Jonzobot,

If you are suggesting benefit in those with eGFR below 30, then you are getting into the territory of Stage 4/5 CKD, not Stage 1/2.

https://www.kidney.org/atoz/content/gfr

Resverlogix has had a planned Stage 5 End Stage Renal Disease trial in holding pattern for over 2.5 years now.

https://clinicaltrials.gov/ct2/show/NCT03160430

Additionally, Resverlogix ran a very small, very short trial in New Zealand in Stage 4/5 CKD patients and found robust changes in circulating inflammatory markers and other proteins after just 1 day of treatment. Those results are published.

https://www.ncbi.nlm.nih.gov/pubmed/29854980

BDAZ